HOME >> MEDICINE >> NEWS
Combination therapy does not appear to benefit cardiac patients before heart catheter procedure

Patients with acute myocardial infarction (MI - heart attack) who are referred for percutaneous coronary intervention (such as angioplasty and stent placement in the coronary artery) do not have a reduction in the amount of damaged heart tissue when administered two drugs compared with a single drug to restore blood flow, according to a study in the February 25 issue of The Journal of the American Medical Association (JAMA).

According to background information in the article, "In hospitals with catheterization facilities, primary percutaneous coronary interventions (PCIs) are better then thrombolysis (drug therapy used to dissolve blood clots) in patients with ST-segment elevation acute MI. Specifically designed randomized trials have also shown that patients with acute MI presenting at hospitals without catheterization facilities benefit more from PCI performed after transfer to centers with catheterization laboratories than from on-site thombolysis."

Adnan Kastrati, M.D., from Deutsches Hezzentrum, Technische Universitat, Munich, Germany, and colleagues from the Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators, assessed whether early administration of the combination of the drugs reteplase plus abciximab produces better reduction of infarct size compared with abciximab alone in patients with acute MI referred for PCI. The study, conducted from May 3, 2001 through June 2, 2003, included 253 patients who were admitted to 13 community hospitals without catheterization facilities (n=186) and to 5 hospitals with catheterization facilities (n=67), within 12 hours of symptoms of an acute MI. Patients randomly received either the combination of reteplase and abciximab (n=125) or abciximab (n=128) alone. All patients were then transferred for PCI. Infarct size was later determined by imaging from a single-photon emission computed tomography (SPECT).

"The final infarct size of the left ventricle, the primary en
'"/>

Contact: Adnan Kastrati, M.D.
kastrati@dhm.mhn.de
JAMA and Archives Journals
24-Feb-2004


Page: 1 2

Related medicine news :

1. Combination treatment helps thyroid cancer patients live longer
2. Combination therapy, not medication alone, most effective for treating children with OCD
3. Combination of erection pill and testosterone gel may benefit men who fail treatment with pill alone
4. Combination therapy w/ ACTOS (pioglitazone HCI) shown to improve components of diabetic dyslipidemia
5. Combination PET/CT should be used to determine stage of non-small cell lung cancer
6. Combination of toxin and poison may be novel treatment for leukemia
7. Combination drug therapy could substantially improve symptoms of rheumatoid arthritis
8. Combination drug therapy offers hope for malaria treatment
9. Combination therapy significantly delays progression of benign prostatic hyperplasia
10. Combination, order of anti-HIV drugs make a difference in first-time recipients
11. Combination of HIV/malaria increases complications during pregnancy

Post Your Comments:
(Date:11/24/2014)... (PRWEB) November 24, 2014 Global ... 6.19 billion by 2020, according to a new ... rates of cardiac arrhythmias clubbed with growing global ... this market. Though still in the budding stage, ... rise in usage rates in the recent times, ...
(Date:11/24/2014)... 2014 Residents of retirement communities in ... year’s SENIORS GOT TALENT, an annual online talent competition ... players to classic crooners, to seniors partying on a ... are indeed living young. , “SENIORS GOT TALENT, while ... cash prize, has always been about highlighting the vibrancy ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured ... Jr, airing via Discovery Channel. Dates and show times ... non-invasive, replaceable, and affordable germ protective device. This segment ... and adhesives to promote hand hygiene in high traffic ... SafeHandles is the desire to make a positive impact ...
(Date:11/24/2014)... Pittsburgh, PA (PRWEB) November 24, 2014 ... as he was trying to cross the street in ... "The driver never saw him. I came up with ... easily visible at night." , He developed the Safety ... night or in low-lighting conditions. The device ensures that ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2
(Date:11/24/2014)... 2014  GlySens Incorporated announced today that it has ... the National Institute of Diabetes and Digestive and Kidney ... Health (NIH).  The grant is intended to support human ... term implantable glucose monitoring system.  Final preparations for launch ... to begin before the end of 2014. ...
(Date:11/23/2014)... Nov. 23, 2014 Anthera Pharmaceuticals, Inc. (Nasdaq: ... F. Truex , President and Chief Executive Officer, will ... Jaffray Healthcare Conference. Anthera will present ... Palace Hotel in New York City ... Anthera Pharmaceuticals is a biopharmaceutical company focused on developing ...
(Date:11/22/2014)... NEWTOWN, Pennsylvania , 21 de noviembre de ... servicios de ensayos clínicos externalizados y tecnologías eClinical, ... su aproximación de ,seguimiento inteligente, para el seguimiento ... El seguimiento inteligente amplía el concepto del seguimiento ... simple reducción de las visitas de seguimiento o ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
Cached News: